Table 1.
Overall patient baseline characteristics.
| No. | (%) | |
|---|---|---|
| Total | 117 | |
| SEX | ||
| male | 40 | 34 |
| female | 77 | 66 |
| AGE (mean ± SD) | 64.5 ± 11.2 | |
| ECOG PS | ||
| 0–1 | 86 | 73.5 |
| ≥2 | 31 | 26.5 |
| SMOKING STATUS | ||
| Non-smoker | 83 | 71 |
| Former + Current smoker | 34 | 29 |
| Adenocarcinoma | 117 | 100 |
| Stage | ||
| IV | 117 | 100 |
| EGFR Mutation | ||
| L858R | 49 | 42 |
| Exon 19 deletion | 68 | 58 |
| PD-L1 expression (TPS%) | ||
| Negative (TPS < 1%) | 45 | 38 |
| Weak (TPS 1–49%) | 45 | 38 |
| Strong (TPS ≥ 50%) | 27 | 24 |
| First-line EGFR-TKIs | ||
| Afatinib | 75 | 64 |
| Erlotinib | 27 | 23 |
| Gefitinib | 15 | 13 |
SD, Standard Deviation; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TPS, Tumor Proportion Scores; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors.